A pilot study of treatment of social phobia with alprazolam
Abstract
Fourteen patients with DSM-III social phobia were treated with alprazolam in an open study. Multiple measures of symptoms and disability showed significant improvement. The symptoms improved during the first and second weeks, and disability improved at 3 weeks and beyond. After medication withdrawal the symptom and disability measures were no longer significantly different from those at baseline.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).